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Stem Cell Transplantation (RIC AlloSCT) for Relapsed
and Refractory Mantle Cell Lymphoma (MCL):
A Study of the British Society for Blood
and Marrow Transplantation
Gordon Cook,1 Graeme M. Smith,1 Keiren Kirkland,2 Julia Lee,2 Rachel Pearce,2
Kirsty Thomson,3 Emma Morris,3 Kim Orchard,4 Simon Rule,5 Nigel Russell,6
Charles Craddock,7 David I. Marks8 on behalf of the Clinical Trials Committee (CTC) of the
British Society for Blood and Marrow Transplantation (BSBMT)Reduced-intensity allogeneic stem cell transplantation (RIC-AlloSCT) is being increasingly considered for pa-
tients with aggressive lymphoma, but limited evidence exists inmantle cell lymphoma (MCL).We report a ret-
rospective study of transplant outcomes of RIC-AlloSCT for MCL in 70 patients (median age, 48 years, range:
30-67 years), with 57 patients receiving an Alemtuzumab-containing regimen. Thirty-four percent of patients
had received a prior autologous stem cell transplant. The 1- and 5-year nonrelapse mortality (NRM) was 18%
(95% confidence interval [CI] 10-27) and 21% (95% CI 12-31), respectively. The incidence of severe (grade III
and IV) acute graft-versus-host disease (aGVHD) was 10%, and the 5-year incidence of chronic GVHD
(cGVHD) was 61%. The cumulative relapse risk was 65% (95% CI 48-77) at 5 years, significantly affected
by disease status at transplant (P 5 .0495), specifically the presence of chemosensitive disease (P 5 .0364).
Fifteen of 18 relapsed patients received donor lymphocyte infustion (DLI) (n 5 14) or a second RIC-
AlloSCT (n5 1), with 11 of 15 currently in CR. The 5-year overall survival (OS) and progression-free survival
(PFS) were 37% (95% CI 25%-56%) and 14% (95%CI 6%-34%), respectively. Age at transplantation and having
\2 prior lines of therapy influenced the OS, whereas having\2 prior lines of therapy was the only factor to
influence PFS. The use of Alemtuzumab in the conditioning was associated with an improved OS at 3 years
(P5 .0271). RIC-AlloSCT is a potential treatment modality for aggressive MCL. For patients relapsing post-
AlloSCT, the disease is salvageable with DLI. The timing of RIC-AlloSCT should be explored in prospective
studies to establish the optimal role in the management of this aggressive lymphoma.
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Mantle cell lymphoma (MCL) comprises 5% of all
cases of non-Hodgkin lymphoma (NHL), with patients
typically presenting with disseminated disease that fre-
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supplemented with rituximab, OS and event-free sur-
vival (EFS) rates of 89% and 79% at 54 months were
reported [8]. The most compelling evidence in support
of a more aggressive treatment approach in MCL has
recently been presented by the Nordic lymphoma
group [9], where after 6 cycles of alternating R-Maxi
CHOP (Maxi CHOP consists of cyclophosphamide
1200 mg/m2, doxorubicin 75 mg/m2, vincristine 2 mg,
and prednisolone 100 mg daily  5, both at capped
doses, given every 21 days) and R-high dose Ara C, the
achieved an ASCT-induced overall relative risk (ORR)
of 96% (55% complete remission [CR], 41% partial
remission [PR]) and 5-year EFS and OS of 63% and
74%, respectively.
Use of myeloablative-conditioned allogeneic stem
cell transplantation (AlloSCT) has been adopted in the
management of MCL, although the high treatment-
related mortality (TRM) and the fact that most pa-
tients with MCL are elderly (median age of 64 years
compared with 53 years for follicular lymphoma [10])
limits the widespread use of this treatment modality
[11,12]. Nonetheless, the existence of the graft-
versus-MCL effect has been demonstrated by delayed
molecular responses following AlloSCT, responses to
donor lymphocyte infusion (DLI) following relapse,
the association of disease response with incidence of
graft-versus-host-disease (GVHD) and, more re-
cently, disease response following AlloSCT with
reduced-intensity conditioning (RIC AlloSCT) [13-
15]. Two recently published series have reported low
rates of PFS with the use of RIC AlloSCT for MCL.
Analysis from the lymphoma working party of the
EBMT reported OS and PFS at 2 years of only
12.8% and 0% in 22 patients with MCL with the
major cause of failure being disease progression [16].
Similarly, the Italian BMT group reported a 3-year
OS of 45% and a 3-year relapse incidence of 81% in
patients with MCL [17]. Therefore, we sought to study
the use of RIC AlloSCT in patients with MCL to
determine the efficacy of this intervention on disease
control, examining the effect of T cell depletion and
the occurrence of GVHD on the disease outcome
from transplant.PATIENTS AND METHODS
Patient Selection and Definitions
For this retrospective study, eligible patients were
identified from the British Society for Blood and
Marrow Transplantation (BSBMT) Data Registry
and additional patient-specific data was acquired di-
rectly from individual centers. Consent for data to be
registered on the BSBMT Registry for use in activity,
outcome, and research analysis was obtained at thetime of transplantation, in line with EBMT directives.
This study was approved and registered by the
BSBMT Clinical Trials Committee. Data from 70 pa-
tients with MCL who were transplanted between 1997
and 2006 from 18 transplant centers (median of 2 pa-
tients per center, range: 1-14) were collected, and the
effect of disease-, patient-, and transplant-specific vari-
ables on outcomes were analyzed. Relapse was defined
as the time to onset of clinical recurrence or disease
progression. Nonrelapse mortality (NRM) was de-
fined as mortality not related to disease recurrence.
Death in CR is considered the event. Progression-
free survival (PFS) was defined as survival in complete
remission, and overall survival (OS) was defined as
time from transplant to death from any cause, with
surviving patients being censored at time of last
follow-up. Patient characteristics are illustrated in
Table 1.Transplant Procedures
All patients received allogeneic stem cell grafts
after RIC. An RIC regimen was defined as one that
could cause reversible myelosuppression when
administered without allogeneic stem cell support,
result in low nonhematologic toxicity, and result in
mixed donor-recipient chimerism, although we do in-
clude BEAM in this category [18]. The regimens used
and transplant details are summarized in Table 1.
Forty-one patients received fludarabine and melphalan
(FM), 22 patients received BCNU, etoposide, cytara-
bine, and melphalan (BEAM); 7 patients received flu-
darabine and busulfan (FB). Fifty-five patients
received in vivo T cell depletion with either alemtuzu-
mab (CAMPATH-1H; n 5 52) or antithymocyte
globulin (ATG; n 5 3). The median alemtuzumab
dose was 50 mg i.v. in divided doses (range: 30-100
mg). Prophylaxis for GVHD was with cyclosporine
(CsA) alone in those who received in vivo T cell deple-
tion and a combination of CsA and methotrexate in
those with T cell-replete grafts. CsA was started on
day 1 at a dose of 3 mg/kg/day intravenously, and
changed to an oral formulation as soon as tolerable.
Stem cell donors were fully matched related sibling
(MRD) in 39 patients, single antigen mismatched sib-
ling in 3 patients, matched unrelated volunteer donor
(MUD) in 25 patients with 3 patients receiving a graft
from a single antigen mismatched MUD. Granulocyte
colony–stimulating factor (G-CSF) mobilized periph-
eral blood stem cells were used for 63 grafts (90%) and
bone marrow was used for 7 grafts (10%). Supportive
care and infection prophylaxis were administered
according to local protocols. Febrile neutropenia was
treated with broad-spectrum intravenous antibiotics
as per institutional guidelines. All blood products
were irradiated to 25 Gy and were derived from
screened CMV seronegative blood donors.
Table 1. Patient Characteristics
N %
Sex
Male 55 79
Female 15 21
Age at diagnosis
Median (min,max) 48.3 (30.7, 67.1)
Stage at diagnosis
unknown 4 6
1 4 6
2 2 3
3 8 12
4 52 73
Bone marrow involvement
unknown 0 0
No 30 38
Yes 40 62
Bulk disease (>5 cm)
unknown 29 41
No 28 39
Yes 13 20
Status at transplant:
CR1 21 30
$CR2 15 21.5
PR1 9 13
$PR2 12 17.5
Relapse/refractory 12 17
Unknown 1 2
Median recipient age at transplant
(years, range)
52.2 (34.7-68.8)
Median donor age at transplant
(years, range)
46.6 (19.4-75.3)
Median time to transplant from
diagnosis (months, range)
28.7 (4.2-114.9)
Donor origin:
MRD/mMRD 42 60
MUD/mMUD 28 40
Graft:
PBSC 63 90
BM 7 10
Sex matching:
F/M 16 24
Other 54 76
CMV serological matching:
Donor Neg/ Recipient Pos 16 22.9
Other 54 77.1
Conditioning Regimens
Fludarabine 150 mg/m2 i.v. and
Melphalan 140 mg/m2 i.v.
41 59
Alemtuzumab 31
No Alemtuzumab 7
ATG 1
Unknown 2
BCNU 300 mg/m2 i.v., etoposide
800 mg/m2 i.v., Cytosine
1600 mg/m2 i.v. & melphalan
140 mg/m2 i.v.
22 31
Alemtuzumab 17
No Alemtuzumab 5
Fludarabine 150 mg/m i.v. and
busulphan 12.8 mg/kg i.v.
7 10
Alemtuzumab 4
ATG 2
No Alemtuzumab/ATG 1
CR indicates complete remission; PR, partial remission; i.v., intravenous;
Neg, seronegative; Pos, seropositive; PBSC, peripheral blood-derived
stem cells; BM, bone marrow-derived stem cells; MRD, matched related
donor; mMRD, mismatched related donor; MUD, matched unrelated
donor; mMUD, mismatched unrelated donor.
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Patients who relapsed or showed disease progres-
sion were given therapeutic DLI, in incremental dos-
ing (106 to 107 CD31 cells/kg) in accordance with
local protocols. Preemptive DLI was used in patients
with persistent disease or mixed T cell lineage chime-
rism at evaluation, in accordance with local protocols.
Patients were treated to maximal response. The dosing
schedule for DLI infusion varied between centers.
Chimerism Analysis
Chimerism studies were performed using fluores-
cein in situ hybridization for X and Y chromosomes or
by microsatellite PCR. DNA was prepared from pre-
transplantation recipient and donor blood. Following
transplantation, peripheral blood mononuclear cells
were cell-sorted into granulocyte, T cell, and B cell prep-
arations, and PCR for highly polymorphic short tandem
repeats (STR) were performed in local laboratories
according to validated methods. Chimerism studies
were not performed in 6 patients because of TRM before
the first chimerism assessment point (day 130). Com-
plete donor chimerism (CDC) was defined as .99%
donor STR in T-lymphocyte and myeloid lineages.
Statistical Analysis
OS and PFSs were calculated by the Kaplan-Meier
method. Univariate comparisons were performed by
the log-rank test and multivariate analysis by Cox
regression. Mortality from relapse or progression of
disease and NRM were calculated as competing risks
and univariate comparisons made by Grey’s method
[19-21]. Current lymphoma-free survival (CLFS), de-
fined as survival without evidence of lymphoma at the
time of most recent assessment, was calculated as previ-
ously described [22]. Multivariate analyses included all
terms withP\ .10 in univariate analysis, and then terms
that were not significant in the multivariate analysis
were removed, to avoid eliminating patients for whom
data on these terms might be missing. NRM and relapse
rate were modeled separately for multivariate analysis,
although in each case the other event was included in
the model as a competing risk. Statistical analysis was
performed using Stata 9.2 and R 2.8.1.RESULTS
Patients
Patient demographic and transplant data is summa-
rized in Table 1. The cohort consisted of 55 male (79%)
and 15 female (21%) recipients with a median age at
transplant of 52.2 years (range: 34.7-68.8 years). The
median interval between diagnosis and transplant was
29 months (range: 4.2-114.9 months) and the median
follow-up is 37 months (range: 3-95 months). The
1422 Biol Blood Marrow Transplant 16:1419-1427, 2010G. Cook et al.number of prior chemotherapy regimens ranged from 1
to 6, with a median of 2, including 40 patients (64%)
who received rituximab at first line (CHOP-R, n 5
30), 13 patients (39%) who received a fludarabine-
containing salvage regimen, and 24 patients (34%)
with a prior autologous transplant. At the time of trans-
plant, 36 (51%) patients were in CR, 21 (32%) patients
in a chemosensitive PR, and 11 (15%) patients had
relapsed/refractory disease.Engraftment and Chimerism
The graft contained a median of 4.97  106/kg
CD341 cells (range: 1.73-28.27). All patients demon-
strated myeloid engraftment, although 1 patient dem-
onstrated autologous engraftment and another
patient presented with late graft failure necessitating
a repeat infusion of donor stem cells. The median
time to neutrophil (.0.5  109/L) recovery was 14
days (range: 9-20 days), and the median time to platelet
(.20 109/L) recovery was 14 days (range: 9-41 days).
Fifty patients (71.4%) experienced an infective compli-
cation within the first 100 days from the AlloSCT,
mostly cytomegalovirus (CMV) reactivation. Results
of chimerism analysis were available in 55 out of 70
(78.6%) patients. Complete donor chimerism (CDC)
was documented in 37 (67.3%) patients at first assess-
ment, with 16 of 55 (29.1%) patients demonstrating
mixed multilineage chimerism.Figure 1. (A) Cumulative incidence of NRM and relapse in 70 patients
with mantle cell lymphoma undergoing RIC AlloSCT. (B) Kaplan-Meier
estimates of OS and PFS for the whole cohort.DLI
Forty-five DLI were used in 27 patients. Sixteen
DLI were administered for relapse/progressive disease
in 14 patients, and 29 DLI were administered for
mixed chimerism in 13 patients. The median maxi-
mum dose of DLI was 1.1  107 T cells/kg (range:
106-108 T cells/kg) after a median of 2 escalating doses
(range: 1-3 doses). All patients who received DLI had
received alemtuzumab as conditioning except 1 patient
who required DLI for mixed chimerism. Of the 13 pa-
tients who received DLI for mixed chimerism all sub-
sequently achieved CDC. The response to DLI is
discussed below. Acute GVHD (aGVHD) occurred
in 3 patients and chronic GVHD (cGVHD) in 10 pa-
tients post-DLI, although, in 5 of 10 patients, DLI-
associated cGVHD occurred more than 2 years after
DLI. Of the 27 patients who received DLI, 7 have
died, 1 as a result of DLI-associated GVHD.
Although 27 patients received DLI, only 13 patients
received sequential doses with a median of 122 days
(range: 55-776) between DLI. For those evaluable
for follow-up, the 3-year OS for mixed chimerism (n
5 9) as the indication for DLI was 89% (43%-98%)
compared with relapse as a reason for DLI (n 5 14)
where the 3 year OS was 79% (46%-93%), which
was not statistically significant (P 5 .86).NRM
At a median follow-up of 37 months (range: 3-95
months), 17 of 70 (24.3%) evaluable patients died of
transplant-related causes, including 8 patients within
100 days of the graft infusion. The most common cause
of death was infection (n 5 10, including disseminated
varicella (n5 1) and adenovirus (n5 1) viral infection),
with concurrent GVHD in 2 patients, complicated by re-
spiratory failure (n 5 1), multiorgan failure (n 5 4), or
both (n 5 2). GVHD was directly responsible for the
death of 7 patients, associated with infection (n 5 2)
and thrombotic thrombocytopenic purpura (n 5 1).
The 100-day NRM cumulative incidence was 11%
(95% CI 5%-20%), with the cumulative incidence of
NRM at 1 and 5 years of 18% (95% CI 10%-27%)
and 21% (95% CI 12%-31%), respectively, as illustrated
in Figure 1A. On univariate analysis, the use of alemtuzu-
mab in conditioning (13% versus 47% at 3 years; P 5
.0017), age at transplant (9% for\52 years versus 33%
for .52 years; P 5 .0178; Figure 2), the presence of
B-symptoms at diagnosis (yes, 30% versus no, 8%; P5
.0376), aGVHD (grade 0-I 12% versus II-IV 34%;
P 5 .0418) and cGVHD (present 22% versus absent
3%; P5 .0494) significantly affected NRM (Table 2).
Table 2. Univariate analysis of OS, PFS, RR, and NRM
OS 3 yrs (%) CI P PFS 3 yrs (%) CI P NRM 3 yrs (%) CI P
Age (yrs)
<52.2 55 35, 71 .041 30 14, 48 .5322 9 .0178
>52.2 41 23, 58 28 12, 46 33
Donor origin:
MRD/MUD 53
42
35, 68
23, 60
.351 3221 16, 488, 38 .584 2261 .0.339
B-symptoms Diagnosis
Yes 45 26, 61 .236 25 11, 42 .587 30 .0376
No 51 28, 70 23 7, 45 8
Status at SCT
CR 60 45, 79 .675 31 18, 54 .648 24 .519
PR 40 25, 65 26 13, 51 28
Refractory 38 8, 100 0 0
Prior lines of Therapy
<2 77 62, 97 .004 43 26, 72 .0283 18 .45
$2 34 21, 56 20 10, 41 24
Alemtuzumab
Yes 54 38, 68 .027 32 18, 46 .075 13 5, 24 .0017
No 38 16, 61 20 4, 43 47 23, 69
Acute GVHD
0-I 55 37, 70 .120 42 25, 58 .086 12 .0403
II-IV 40 21, 57 0 34
Chronic GVHD
Present 54 32, 71 .599 22 8, 40 .249 22 12, 31 .0494
Absent 56 34, 73 43 23, 62 3
GVHD indicates graft-versus-host disease; OS, overall survival; PFS, progression-free survival; NRM, nonrelapse mortality; CR, complete response; PR,
partial response; RR, relapse risk; SCT, stem cell transplantation.
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All patients were available for evaluation of
aGVHD. aGVHD occurred in 27 of 70 (39%) pa-
tients, although most were grade I (n 5 17, 24%). Se-
vere aGVHD (grade III and IV) was seen in 7 (10%)
patients and no difference in the overall incidence of
aGVHD was seen between recipients of a related or
unrelated graft (related 36% versus unrelated 43%;
P 5 .62 by Fisher’s exact test). Sixty of the 70 patients
were evaluable for cGVHD, which was present in 29 of
60 (61%) of patients at 5 years with a median time to
onset of 13.6 months (range: 5.6-65.6 m). The propor-
tion of limited and extensive cGVHD were similar
(41% versus 34% at 5 years, respectively) and no
impact of the donor origin was evident on the
incidence of cGVHD (related 54% versus inrelated
43% at 5 years; P 5 .87 by Fisher’s exact test).Survival and Disease Response
At the first available response assessment (day190;
n 5 61), 29 (48%) patients achieved a CR with 22
(37%) maintaining a CR, 2 (3%) patients achieving
a PR, 3 (5%) patients demonstrating a minimal/no
response with 4 (6%) patients demonstrating early
relapse/progression. With a median follow-up of 37
months (range: 3-95 months), 33 patients have
relapsed and 18 patients have died as a result of disease
progression. Fifteen of 33 patients with relapsed dis-
ease have been retreated with DLI (n5 14) or a second
RIC-AlloSCT (n 5 1) and at last follow-up, 11 of 15
remain in CR with the remaining 4 patients alivewith disease. The median time to relapse was 346
days (range: 264-640 days). The cumulative relapse
risk was 65% (95% CI 48-77) at 5 years and, in a uni-
variate analysis, disease status at transplant (CR versus
PR versus refractory; P 5 .0495) and the presence of
chemosensitive disease (P 5 .0364) were predicted
for relapse at 3 years. Although not significant, a trend
toward increased relapse risk when alemtuzumab was
incorporated within the transplant conditioning pro-
tocol was noted (56% 95% (CI 39-69) with alemtuzu-
mab compared with 33% (95% CI 12-57) without
alemtuzumab; P 5 .305, Figure 4D).
At last follow-up, 35 patients were alive; 19
(54.3%) patients in ‘‘original post-AlloSCT’’ CR and
11 (31.4%) patients in a subsequent CR following dis-
ease progression management. The 5-year probability
estimates of OS and PFS were 37% (95% CI 25%-
56%) and 14% (95% CI 6%-34%), respectively
(Figure 1B). Patients who relapse after AlloSCT can
achieve sustained remissions after treatment with
adoptive immunotherapy (DLI). CLFS, defined as sur-
vival without evidence of lymphoma at the time of
most recent assessment, was estimated as 40% (95%
CI 20, 60) at 3 years. For patients transplanted in
CR, PR, and with refractory disease, the 3 year OS
and PFS probability estimates were: CR 60% (95%
CI 45%-79%) and 31% (95% CI 18%-54%), PR
40% (95% CI 25%-65%) and 26% (95% CI 13%-
51%), and refractory disease 38% (95% CI 8%-
100%) and 0%, P 5 .675 and P 5 .648, respectively.
In a univariate analysis, younger age at transplant
(P 5 .0409) and having received \2 prior lines of
Figure 2. Kaplan-Meier estimates of OS (A) and PFS (B) based on age
at time of RIC AlloSCT.
Figure 3. Kaplan-Meier estimates of overall survival based on the
presence of acute (A), chronic (B) GVHD, and DLI (C) use post-RIC
AlloSCT.
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OS at 3 years (Table 2 and Figure 3). The use of alem-
tuzumab in the conditioning was associated with an
improved OS at 3 years (54% 95% CI 38%-68% cf.
38% 95% CI 16%-61%, P 5 .0271, Figure 4A).
In contrast, having received \2 lines of therapy
(P5 .0283) was the only factor to have a significant im-
pact on PFS at 3 years (Table 2 and Figure 3), although
a trend to better PFS in those who received alemtuzu-
mab was evident (32% 95% CI 18%-46% cf. 20%
95% CI 4-43, P 5 .075).
In patients who relapsed post-AlloSCT (n5 36) and
underwent salvage therapy, univariate analysis identi-
fied that those who received adoptive immunotherapy
with DLI (DLI: 60% 95% CI 40%-91% cf. no DLI
0%, P 5 .006, Figure 3C) and those who experienced
cGVHD postsalvage (cGVHD: 52% 95% CI 29%-
93% versus no cGVHD 17% (95% CI 5%-55%),
p5 .015) demonstrated better OS at 3 years postrelapse,
indicative of an immunological antitumor effect. The
incidence of aGVHD did not affect OS.
In multivariate analyses, the use of alemtuzumab in
the conditioning regimen was significantly associated
with an increased relapse risk (P 5 .042; hazard ratio
[HR] 3.557’; 95% CI 1.05-12.1), whereas chemosensi-
tivity at transplant was associated with reduced relapserate (P 5 .046; HR 0.402, 95% CI 0.164-0.985).
Alemtuzumab use was significantly associated with
reduced NRM (P 5 .002; HR 0.183, 95% CI
0.06-0.53; Figure 4C), whereas increased age at trans-
plant was associated with increased NRM (P 5 .022;
HR 1.06 per year, 95% CI 1.01-1.12).
Figure 4. Kaplan-Meier estimates of the effect of exposure to Alemtuzumab (CAMPATH-1H) on OS (A), EFS (B), NRM (C), and RR (D).
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Since its recognition in the Revised European-
American Lymphoma classification as a distinct entity,
the clinical course of MCL remains unsatisfactory,
with a median survival of 3 to 4 years from diagnosis
as a result of temporary responses to conventional
chemotherapy schedules and high recurrence rates,
with reported 5-year OS rates improved from 22%
in 1975-1986 to 47% in 1996-2004 [23]. However,
the role of AlloSCT in MCL remains to be determined
though early reports suggested a potential role of RIC
regimens in the management of advanced disease
[13,15,24]. Most studies reporting the effect of
AlloSCT in the management of MCL have resulted
from subgroup analysis of larger cohorts of
heterogeneous histological subtypes of malignant
lymphoma [17,25-28].
The patient cohort in this study was heavily
pretreated with advanced MCL, with a median of 3
previous chemotherapy regimens for a majority
(79%) of stage IV disease at presentation and approx-
imately one-third of patients having previously failed
an ASCT. Only 51% of patients were in CR at trans-
plantation and the rest had variable amounts of resid-
ual disease, including some with refractory disease.
The effect of prior therapies and age are clearly de-
monstrable in OS and NRM rates (Table 2), andthus the use of AlloSCT in an earlier phase of disease
management is worthy of investigation.
Although the allo-reactivity of the graft is fre-
quently considered detrimental to the recipient
(GVHD), the beneficial effect of antitumor T cell
responses in eliminating transformed cells exists to
varying degrees between malignant disorders [29].
The effect of in vivo T cell depletion on OS, PFS,
and relapse rates (RR) is illustrated in this study.
Although alemtuzumab reduces the NRM, an increase
in RR is suggestive of the existence of a graft-versus-
MCL effect, which may be potentially diminished
through the depletion of antitumor immune effector
cells, although this, as a result of the low numbers in
this study cohort, could not be demonstrated. We re-
port a low level of GVHD in this cohort of patients,
largely the result of alemtuzumab, but were unable
to demonstrate a relationship between OS and PFS
with the presence of GVHD, except in those who re-
lapsed and were subsequently treated with adoptive
immunotherapy. Despite this increase in RR, noted
within the first year post-AlloSCT in the majority of
cases, such relapsed disease is amenable to salvage
therapy through the use of DLI as adoptive immuno-
therapy. Patients who relapse after AlloSCT can
achieve sustained remissions after treatment with
adoptive immunotherapy (DLI). Lymphoma-free
survival (LFS), defined as survival without evidence
1426 Biol Blood Marrow Transplant 16:1419-1427, 2010G. Cook et al.of relapse at any time posttransplant, underrepresents
those patients restored to complete remission. It has
become established that CLFS, defined as survival
without evidence of lymphoma at the time of most
recent assessment, can gauge the contribution of treat-
ment for relapse to the efficacy of AlloSCT [22]. We
therefore calculated the CLFS in the current cohort
demonstrating the effect of postgraft immunothera-
peutic intervention. As such, the cohort demonstrates
a good 5-year OS, though the durability of the DLI-
associated salvage response remains to be determined
and longer follow-up is required. Previous studies
have reported a similar effect on the incidence of
relapse and consequential use of DLI in patients with
lymphoproliferative disorders who underwent RIC
AlloSCT employing alemtuzumab [30,31]. The
results in this study are indicative of the effect of
alemtuzumab on the NRM and on the potential
salvageable nature of MCL relapses post-AlloSCT.
As such, utilizing alemtuzumab in the conditioning
regimen of an RIC protocol should be coupled with
a preemptive/prophylactic strategy of DLI to facilitate
the balance of improved safety without compromising
the antitumor effect. The timing of the preemptive
DLI should be considered carefully, as previous stud-
ies have demonstrated that the delayed infusion of
DLI for both disease persistence/progression and
mixed chimerism is associated with an improved out-
come and reduced DLI-associated GVHD [32,33].
We have demonstrated that OS at 5 years in our
cohort of patients is 37% irrespective of their remis-
sion status at the time of transplant. The OS in patients
transplanted when in CR, whether first, second, or
third, demonstrated better survival than those with re-
sidual disease at the time of transplant (58%-67% cf.
30%-50%), although those with primary refractory
disease demonstrated a comparable OS to those
transplanted in CR (59%). These differences were
not statistically significant; however, one might expect
patients with chemosensitive disease to benefit the
most from RIC AlloSCT as has previously been shown
in studies of aggressive lymphoma [17,25-27]. A
previous single-center study reported 85% EFS after
RIC AlloSCT in advanced and/or recurrent MCL,
although follow-up was limited in this report [13].
The utilization of the more recently advocated Mantle
Cell International Prognostic Index and tumor cell
Ki67 staining may help to differentiate which patients
have a higher risk of relapse from primary therapy and
would benefit most from an RIC AlloSCT as an up-
front therapeutic intervention [34,35].
In summary, our data confirms that RIC AlloSCT
is a potentially suitable treatment modality for patients
with aggressive relapsed/recurrent MCL who have
failed treatment with conventional chemotherapy and
ASCT. The toxicity profile is acceptable, especially
when alemtuzumab is used in conditioning to impartin vivo T cell depletion, although this may be associ-
ated with an increased risk of disease progression and
relapse. Nonetheless, such disease progression is ame-
nable to salvage with adoptive immunotherapy medi-
ated through the use of DLI, providing evidence of
a graft-versus-MCL effect. Close monitoring of chi-
merism and timely preemptive use of DLI is recom-
mended; this requires prospective examination. The
timing and optimum conditioning regimen of RIC Al-
loSCT should be explored in prospective studies to es-
tablish the optimal role of AlloSCT in the
management of this aggressive lymphoma.ACKNOWLEDGMENTS
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